The FDA warns off-brand versions of the popular weight-loss drugs might not contain the same ingredients as the prescription products and may not be safe or effective.
FILE - This Tuesday, April 3, 2018 file photo shows a closeup of a beam scale in New York. The Food and Drug Administration is warning consumers, Thursday, June 1, 2023, not to use off-brand versions of the popular weight-loss drugs Ozempic and Wegovy sold online because they might not contain the same ingredients as the prescription products and may not be safe or effective. The U.S.
The trouble is that those versions, often sold online, contain a version of semaglutide that is used in lab research and has not been approved for use in people.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
The View's Ana Navarro Details Weight Loss 'Struggle' Amid Ozempic CrazeAna Navarro opened up about trying to maintain 'healthy habits' after being accused of using Ozempic for weight loss — details
Leer más »
Things To Never Say To Someone Taking OzempicThough it is not FDA-approved for weight loss, Ozempic, an injectable drug used to treat diabetes, has helped users shit and puke away the pounds. These are things that you should never say to someone taking Ozempic.
Leer más »
FDA considers temporary cancer drug imports from unapproved companies to ease U.S. shortageShortages of cisplatin and carboplatin, bedrock cancer treatments, have forced some hospitals to ration the drugs.
Leer más »
FDA’s distorted priorities are costlyThe Food and Drug Administration is the nation’s most ubiquitous regulatory agency, responsible for overseeing products — drugs, medical devices, tobacco products, and most foods — that account for about 20 cents of every dollar spent by consumers. It is currently going through a rough patch, with…
Leer más »
FDA finalizes arsenic limits in apple juiceThe FDA says inorganic arsenic is associated with various health problems, including cancer, cardiovascular disease and developmental disabilities.
Leer más »